FDA Approves First Gene Therapy to Restore Hearing

FDA Approves First-Ever Gene Therapy for Genetic Hearing Loss

On April 23, 2026, the U.S. Food and Drug Administration approved Otarmeni (lunsotogene parvec-cwha), making it the first gene therapy ever approved to treat genetic hearing loss. Developed by Regeneron Pharmaceuticals, the therapy targets a rare but devastating form of congenital deafness caused by biallelic mutations in the OTOF gene — a condition for which, until now, no disease-modifying treatment existed. The approval marks a turning point not only for the roughly 50 babies born each year in the United States with this condition, but for the broader field of gene therapy and auditory medicine.

"Today's approval is a significant milestone in the treatment of genetic hearing loss," said Dr. Marty Makary, M.D., M.P.H., FDA Commissioner, in the agency's official press announcement.

What Otarmeni Is and How It Works

Otarmeni is indicated for pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the OTOF gene. The OTOF gene normally instructs the body to produce otoferlin, a protein essential for transmitting sound signals from the inner ear's hair cells to the auditory nerve and brain. Without functional otoferlin, individuals are born profoundly deaf, with cochlear implants previously representing the only available intervention — one that requires long-term hardware dependence and does not replicate natural hearing.

Otarmeni is a one-time biologic-device combination product delivered as a single dose per ear. It is surgically infused into the cochlea via a syringe and catheter connected to an infusion pump, in a procedure the FDA describes as similar to cochlear implantation. The therapy employs a dual adeno-associated virus (AAV) vector system — a design that addresses a specific technical constraint: the OTOF gene's coding sequence is too large to fit within a single AAV capsid. The payload is instead split across two vectors, which then reconstitute within the target cell. According to allsci.com, this dual-vector design had not previously supported an approved product, making Otarmeni's approval a technical milestone in its own right.

The application received orphan drug, rare pediatric disease, fast track, and regenerative medicine advanced therapy (RMAT) designations from the FDA. Genetic mutations cause approximately half of all congenital hearing loss, according to the agency, and variants in the OTOF gene account for 2% to 8% of inherited, non-syndromic hearing loss cases.

Trial Results: Hearing Restored, Including the Ability to Hear Whispers

The FDA's approval was based on results from the Phase 1/2 CHORD trial, which enrolled 20 pediatric patients aged 10 months to 16 years. Of the 20 patients evaluable for efficacy, 80% — 16 of 20 — experienced improved hearing at 24 weeks, meeting the trial's primary endpoint. Among those followed for at least 48 weeks, 42% (5 of 12) achieved normal hearing levels, including the ability to hear whispers. Additionally, 70% of trial participants — 14 of 20 — demonstrated auditory brainstem responses at or below 90 dB at 24 weeks, meeting the trial's key secondary endpoint.

According to NPR, the hearing ability demonstrated in trial participants has lasted at least two years so far. The durability of results beyond that window remains an open question that ongoing follow-up will need to address.

"It's the first time in history there's a new drug for hearing loss," said Zheng-Yi Chen, associate scientist at Mass Eye and Ear in Boston, who was not involved in the trial, speaking to NPR.

A Record-Setting Approval Under a New FDA Program

The FDA issued its approval just 61 days after the Biologics License Application (BLA) was filed — tied for the fastest BLA approval in modern FDA history. The expedited review was facilitated through the agency's Commissioner's National Priority Voucher (CNPV) pilot program. Otarmeni is the sixth product approved under the CNPV program and the first gene therapy to receive approval through it, according to Fierce Pharma.

Otarmeni is also Regeneron's first approved gene therapy. The therapy was originally developed as DB-OTO by Decibel Therapeutics, a company Regeneron acquired in 2023 for $109 million. The European Medicines Agency has also granted Orphan Drug Designation for the therapy, and Regeneron has indicated regulatory submissions are planned in additional markets.

President Donald Trump publicly touted the approval during an Oval Office announcement on April 23, 2026, connected to a drug pricing arrangement with Regeneron on the self-pay platform TrumpRx, according to NBC News.

Free to Eligible U.S. Patients — With Caveats

In a striking departure from standard gene therapy economics — where price tags have reached as much as $2 million to $3 million for a single patient, according to analyst Evan Seigerman of BMO Capital Markets as cited by CNN — Regeneron announced it will provide Otarmeni at no cost to eligible patients in the United States.

"We are providing Otarmeni for free in the U.S. to remove financial barriers and facilitate equitable access to Otarmeni," a Regeneron spokesperson told Managed Healthcare Executive. The company added that out-of-pocket costs related to the surgical administration procedure may still apply.

According to Managed Healthcare Executive, Otarmeni is expected to be available within weeks, with Regeneron actively working with treatment centers to ensure readiness.

The pricing decision drew attention from health policy observers. "Regeneron has shown us that one option we can consider that will ensure affordable access for patients to these therapies is to not charge the health system for the therapy," said Sarah Emond, president and CEO of the Institute for Clinical and Economic Review, speaking to NBC News.

Why This Approval Matters Beyond the Numbers

In purely epidemiological terms, OTOF-related deafness affects a small population — approximately 50 babies born in the U.S. each year. But the approval carries significance that extends well beyond its immediate patient pool.

"The FDA approval of Otarmeni signals a new era in the treatment of genetic forms of hearing loss, where reinstating 24/7 natural hearing is now possible," said A. Eliot Shearer, MD, PhD, an otolaryngologist in the Department of Otolaryngology and Communication Enhancement at Boston Children's Hospital and Associate Professor of Otolaryngology-Head and Neck Surgery at Harvard Medical School.

Regeneron's co-founder and president, Dr. George Yancopoulos, framed the achievement in broader terms: "We want to make an example of how science, and in this case biotech, can really deliver a gift to people – in this case, the gift of hearing," he told CNN.

"I'm absolutely thrilled," said Jonathon Whitton, vice president for genetic medicines at Regeneron Pharmaceuticals, speaking to NPR.

The dual-AAV vector approach validated by Otarmeni's approval could open a pathway for future therapies targeting other large-gene disorders that were previously considered out of reach for AAV-based delivery systems. And while OTOF variants represent only 2% to 8% of inherited non-syndromic hearing loss, dozens of other genetic causes of deafness exist — each a potential future target.

A Note on Cultural and Ethical Dimensions

Not all responses to the approval have been uniformly celebratory. Some members of the Deaf community and scholars of disability history have raised questions about how gene therapies for deafness are framed culturally and politically.

"These kind of genetic therapies seem to reinforce this idea of deafness being a problem in need of eradication, and that the only solution for disabled people to fully assimilate into society is through a medical intervention," said Jaipreet Virdi, who studies the history of medicine, technology and deafness at the University of Victoria in Canada, speaking to NPR.

These perspectives do not diminish the medical achievement, but they serve as an important reminder that scientific advances in sensory medicine intersect with longstanding questions about disability identity, community, and autonomy. As gene therapies for hearing loss expand — and expand they likely will — those conversations will need to be part of the broader public discourse.

What Comes Next

Otarmeni's approval is expected to accelerate research and investment in gene therapies for other forms of genetic hearing loss. The regulatory pathway established through the CNPV program, combined with the clinical proof-of-concept now on record, gives the field clearer footing for future development efforts.

Regeneron is pursuing regulatory submissions in additional international markets following the European Medicines Agency's Orphan Drug Designation. Longer-term durability data from CHORD trial participants will be critical to establishing the therapy's full clinical profile, particularly given that only two years of follow-up data are currently available.

For now, Otarmeni represents a genuine first — the first approved gene therapy for hearing loss, the first dual-AAV product to reach approval, and the first gene therapy cleared under the FDA's CNPV pilot program. Those are meaningful milestones by any measure, and the medical community will be watching closely as the therapy moves from trial to real-world use in the weeks ahead.

For more tech news, visit our news section.